x
Filter:
Filters applied
- Melanoma
- Garbe, ClausRemove Garbe, Claus filter
- nonmelanoma skin cancerRemove nonmelanoma skin cancer filter
Keyword
- CI2
- confidence interval2
- NMSC2
- AAPC1
- age-standardized incidence rate1
- age-standardized mortality rate1
- ASIR1
- ASMR1
- average annual percentage change1
- basal cell carcinoma1
- BCC1
- CIR1
- CMR1
- crude incidence rate1
- crude mortality rate1
- cSCC1
- cutaneous squamous cell carcinoma1
- hazard ratio1
- HR1
- mortality rate1
- MR1
- PNI1
- SCC1
- TNM1
Melanoma
2 Results
- Original Article Clinical ResearchOpen Archive
Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study
Journal of Investigative DermatologyVol. 137Issue 11p2309–2315Published online: July 20, 2017- Thomas K. Eigentler
- Ulrike Leiter
- Hans-Martin Häfner
- Claus Garbe
- Martin Röcken
- Helmut Breuninger
Cited in Scopus: 82Cutaneous squamous cell carcinoma (cSCC) is an increasing health burden in white populations. We prospectively assessed risk factors for tumor-specific and overall survival in 1,434 patients who underwent surgery for cSCC between January 24, 2005, and May 29, 2015. A total of 2,149 invasive cSCCs were analyzed. Univariate and multivariate survival analyses included tumor thickness, horizontal size, body site, histological differentiation, desmoplastic growth, history of multiple cSCCs, and immunosuppression. - Original Article EpidemiologyOpen Archive
Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany
Journal of Investigative DermatologyVol. 137Issue 9p1860–1867Published online: May 6, 2017- Ulrike Leiter
- Ulrike Keim
- Thomas Eigentler
- Alexander Katalinic
- Bernd Holleczek
- Peter Martus
- and others
Cited in Scopus: 108Increasing incidence rates (IRs) of nonmelanoma skin cancer (NMSC) in white populations have been described worldwide. Cancer registry data from the Saarland and Schleswig-Holstein federal states were used to analyze incidence and mortality trends in Germany. Age-standardized rates were compared with crude rates to assess disease burden. Joinpoint regression models were used to estimate annual percentage changes and 95% confidence intervals, allowing us to assess temporal trends between 1970 and 2012.